• Je něco špatně v tomto záznamu ?

Sebelipase alfa for lysosomal acid lipase deficiency: 5-year treatment experience from a phase 2 open-label extension study

V. Malinová, M. Balwani, R. Sharma, JB. Arnoux, J. Kane, CB. Whitley, S. Marulkar, F. Abel

. 2020 ; 40 (9) : 2203-2214. [pub] 20200809

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020204

BACKGROUND AND AIMS: Lysosomal acid lipase deficiency is characterized by hepatomegaly and dyslipidaemia, which can lead to cirrhosis and premature atherosclerosis. Sebelipase alfa is an approved recombinant human lysosomal acid lipase. In an open-label extension study of adults with lysosomal acid lipase deficiency (LAL-CL04), sebelipase alfa treatment for 1 year reduced serum transaminase levels and liver fat content and improved serum lipid levels. METHODS: Final data from LAL-CL04 are reported herein for patients who received sebelipase alfa infusions (1.0 or 3.0 mg/kg every other week) for up to 5 years. RESULTS: Of 8 patients enrolled, 7 received sebelipase alfa for 224-260 weeks; 1 was lost to follow-up. Median baseline levels of alanine aminotransferase and aspartate aminotransferase (81.5 and 50.0 U/L, respectively) were decreased through the end-of-study visit (54.0 and 34.0 U/L). Median low-density lipoprotein cholesterol decreased from 113 to 78 mg/dL, total cholesterol decreased from 171 to 132 mg/dL, and high-density lipoprotein cholesterol increased from 37 to 42 mg/dL. Most treatment-emergent adverse events were nonserious (99%), mild/moderate (98%) and unrelated to sebelipase alfa (87%); no patient discontinued as a result of treatment-emergent adverse events. One patient had 2 serious treatment-emergent adverse events (cholecystitis and cholelithiasis; assessed as unlikely related to sebelipase alfa). Two patients had 20 nonserious infusion-associated reactions in weeks 6-38; all were manageable. One patient tested positive for antidrug antibodies (single occurrence). CONCLUSIONS: Sebelipase alfa was well tolerated and improved serum transaminase and lipid levels for up to 5 years in adults with lysosomal acid lipase deficiency. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov record NCT01488097.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020204
003      
CZ-PrNML
005      
20210830101832.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/liv.14603 $2 doi
035    __
$a (PubMed)32657505
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Malinová, Vĕra $u Department for Metabolic Diseases, Children's Clinic, General Faculty Hospital and First Faculty of Medicine of Charles University in Prague, Prague, Czech Republic
245    10
$a Sebelipase alfa for lysosomal acid lipase deficiency: 5-year treatment experience from a phase 2 open-label extension study / $c V. Malinová, M. Balwani, R. Sharma, JB. Arnoux, J. Kane, CB. Whitley, S. Marulkar, F. Abel
520    9_
$a BACKGROUND AND AIMS: Lysosomal acid lipase deficiency is characterized by hepatomegaly and dyslipidaemia, which can lead to cirrhosis and premature atherosclerosis. Sebelipase alfa is an approved recombinant human lysosomal acid lipase. In an open-label extension study of adults with lysosomal acid lipase deficiency (LAL-CL04), sebelipase alfa treatment for 1 year reduced serum transaminase levels and liver fat content and improved serum lipid levels. METHODS: Final data from LAL-CL04 are reported herein for patients who received sebelipase alfa infusions (1.0 or 3.0 mg/kg every other week) for up to 5 years. RESULTS: Of 8 patients enrolled, 7 received sebelipase alfa for 224-260 weeks; 1 was lost to follow-up. Median baseline levels of alanine aminotransferase and aspartate aminotransferase (81.5 and 50.0 U/L, respectively) were decreased through the end-of-study visit (54.0 and 34.0 U/L). Median low-density lipoprotein cholesterol decreased from 113 to 78 mg/dL, total cholesterol decreased from 171 to 132 mg/dL, and high-density lipoprotein cholesterol increased from 37 to 42 mg/dL. Most treatment-emergent adverse events were nonserious (99%), mild/moderate (98%) and unrelated to sebelipase alfa (87%); no patient discontinued as a result of treatment-emergent adverse events. One patient had 2 serious treatment-emergent adverse events (cholecystitis and cholelithiasis; assessed as unlikely related to sebelipase alfa). Two patients had 20 nonserious infusion-associated reactions in weeks 6-38; all were manageable. One patient tested positive for antidrug antibodies (single occurrence). CONCLUSIONS: Sebelipase alfa was well tolerated and improved serum transaminase and lipid levels for up to 5 years in adults with lysosomal acid lipase deficiency. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov record NCT01488097.
650    _2
$a dospělí $7 D000328
650    _2
$a alanintransaminasa $7 D000410
650    _2
$a lidé $7 D006801
650    12
$a sterolesterasa $7 D002787
650    12
$a Wolmanova nemoc $x farmakoterapie $7 D015223
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Balwani, Manisha $u Department of Genetics and Genomic Sciences and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
700    1_
$a Sharma, Reena $u Department of Endocrinology and Metabolic Medicine, Salford Royal Foundation NHS Trust, Salford, UK
700    1_
$a Arnoux, Jean-Baptiste $u Department of Inherited Metabolic Diseases, Hôpital Necker-Enfants Malades, Paris, France
700    1_
$a Kane, John $u Department of Medicine, University of California San Francisco, San Francisco, CA, USA
700    1_
$a Whitley, Chester B $u Advanced Therapies Program, and Gene Therapy Center, University of Minnesota, Minneapolis, MN, USA
700    1_
$a Marulkar, Sachin $u Alexion Pharmaceuticals, Inc., Boston, MA, USA
700    1_
$a Abel, Florian $u Alexion Pharmaceuticals, Inc., Boston, MA, USA
773    0_
$w MED00007623 $t Liver international : official journal of the International Association for the Study of the Liver $x 1478-3231 $g Roč. 40, č. 9 (2020), s. 2203-2214
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32657505 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101832 $b ABA008
999    __
$a ok $b bmc $g 1690906 $s 1140650
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 40 $c 9 $d 2203-2214 $e 20200809 $i 1478-3231 $m Liver international $n Liver Int $x MED00007623
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace